ERBB2 and breast carcinoma: LA-ICP-MS enabled insight into the heterogeneous breast cancer cell uptake of Rh-sar-PD-trastuzumab in vitro and uptake in HER2-positive HCC1954 breast cancer tumours, and for the first time, in developing ovarian follicles in vivo.